Do you consider SABR for oligometastatic disease in patients with TP53 germline mutation?
In a patient with their second cancer, with oligometastatic disease, do the risks of RT related second malignancies outweigh the benefits?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center
Answered on
The question at its core is asking would you give RT to a patient with a genetic condition making them more susceptible to RT-induced secondary cancers. This case discussed TP53 mutation associated with Li-Fraumeni syndrome.
However, the case is a patient with oligometastatic disease. This is challen...
Join for free or sign in to see the full answer